SHARE

France, Innovation, 2017

Telomium continues to develop their product

15th July 2019

Telomium, one of the winners of the French Innovation Journey from Education to Business

After applying the vaccine to three monkeys without secondary reactions, Telomium continues to develop their immunotherapy product against cancer.

Telomium is a biotechnology company developing a therapeutic product for cancer immunotherapy. Their first-in-class ribonucleoprotein vaccine has the ability to mimic a viral attack and induce an auto-immune reaction targeted against any form of cancer, without causing significant side effects. This self-vectored and self-adjuvanted vaccine is prepared from a patented, safe, competitive and scalable yeast-based technology using a breakthrough innovation in the production of recombinant telomerase.

After defining the best use of their product, Telomium plans to raise founds in order so start their regular preclinical development then performing clinical trials in humans and setting a deal with a big pharma group

EHDS report connects innovators and European Commission

EHDS report connects innovators and European Commission

Report supports Euopean Commission's EHDS creation

Find out more

EIT HEI Initiative launches new call for proposals

EIT HEI Initiative launches new call for proposals

Improving HEI innovation capacity

Find out more

24 start-ups selected for Bridgehead programme

24 start-ups selected for Bridgehead programme

Support to expand presence to new markets

Find out more